1 |
Burris H, Eckhardt J, Fields S, et al (1993). Phase II trial of Taxotere with non-small cell lung cancer. Proc Am Soc Clin Oncol, 12, 335.
|
2 |
Cho KH Song YB, Choi IS, et al (2006). A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer. Jpn J Clin Oncol, 36, 50-4.
DOI
|
3 |
Cobo M, Gutierrez V, Alcaide J, et al (2007). A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced nonsmall- cell lung cancer and good performance status. Lung Cancer, 56, 255-62.
DOI
|
4 |
Coskun U, Kaya AO, Buyukberber S, et al (2008). Single agent gemcitabine in the second-line treatment of advanced nonsmall cell lung cancer after treatment with taxane + platinum regimens. Med Oncol, 25, 133-6.
DOI
|
5 |
Crino L, Mosconi AM, Scagliotti GV, et al (1999). Gemcitabine as second-line treatment for advanced non-small-cell lung cancer, A phase II trial. J Clin Oncol, 17, 2081-5.
DOI
|
6 |
Fossella FV, De Vore R, Kerr RN, et al (2000). Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol, 18, 2354-62.
DOI
|
7 |
Fossella FV, Lee JS, Shin DM, et al (1995). Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol, 13, 645-51.
DOI
|
8 |
Gandara DR, Vokes E, Green M, et al (1997). Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer, a confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol, 16, 454a.
|
9 |
Gillenwater HH, Tynan M, Natoli S, et al (2000). Second-line gemcitabine in refractory stage IV non-small-cell lung cancer, A phase II trial. Clin Lung Cancer, 2, 133-8.
DOI
|
10 |
Gridelli C, Perrone F, Gallo C, et al (1999). Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC), A phase II trial. Anticancer Res, 19, 4535-8.
|
11 |
Hertel LW, Boder GB, Kroin JS, et al (1990). Evaluation of the antitumor activity of gemcitabine (20, 20-difluoro-20- deoxycytidine). Cancer Res, 50, 4417-22.
|
12 |
Juergens R, Brahmer J, Ettinger D (2007). Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer, sequence does matter. Cancer Chemother Pharmacol, 59, 621-9.
DOI
|
13 |
Kosmas C, Tsavaris N, Syrigos K, et al (2007). A phase I-II study of bi-weekly gemcitabine and irinotecan as secondline chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol, 59, 51-9.
|
14 |
Lara PN Jr, Gumerlock PH, Mack PC, et al (2004). Gemcitabine in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy, A phase II California cancer consortium trial. Clin Lung Cancer, 6, 102-7.
DOI
|
15 |
Le Chevalier T. (1995). Docetaxel, meeting the challenge of nonsmall cell lung cancer management. Anticancer Drugs, 6, 13-7.
DOI
|
16 |
Lund B, Kristjansen PEG, Hansen HH (1993). Clinical and preclinical activity of 20,20-difluoro-20- difluorodeoxycytidine (gemcitabine). Cancer Treat Rev, 19, 45-55.
|
17 |
Mattson K, Le Chevalier T, Stupp R, et al (1996). Preliminary report of Phase II study of docetaxel ( ) in locally advanced or metastatic non-small cell lung cancer. Ann Oncol, 7, 429a.
|
18 |
Robinet G, Kleisbaurer JP, Thomas P, et al (1996). Phase II study of Taxotere (docetaxel) in advanced or metastatic non-small cell lung cancer previously treated with platinum. Ann Oncol, 7, 96-7.
DOI
|
19 |
Sculier JP, Lafitte JJ, Berghmans T, et al (2000). A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. Lung Cancer, 29, 67-73.
|
20 |
Robinet G, Kleisbaurer JP, Thomas P, et al (1997). Phase II study of docetaxel (Taxotere) in first and second-line NSCLC. Proc Am Soc Clin Oncol, 16, 480.
|
21 |
Shepherd F, Dancey J, Ramlau R, et al (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.
DOI
|
22 |
Van Kooten M, Traine G, Cinat G, et al (1999). Single agent gemcitabine in pretreated patients with non-small-cell lung cancer, results of an Argentinean multicentre phase II trial. Br J Cancer, 81, 846-9.
DOI
|
23 |
van Putten JW, Baas P, Codrington H (2001). Activity of singleagent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer, 33, 289-98.
DOI
|
24 |
Yokoyama A, Kurita Y, Watanabe K (1994). Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer, docetaxel cooperative study group for lung cancer. Gan To Kagaku Ryoho, 21, 2609-16.
|